Latest Articles
Organon's non-hormonal endometriosis hope dashed - FirstWord Pharma
Organon's non-hormonal endometriosis hope dashed FirstWord Pharma
Published: July 2, 2025, 3:25 p.m.
Organon drug for endometriosis falls short in mid-stage study - BioPharma Dive
Organon drug for endometriosis falls short in mid-stage study BioPharma Dive
Published: July 2, 2025, 2:33 p.m.
When Period Pain Is More Than Normal: Ugandan Women Battle Endometriosis and Infertility - Nilepost News
When Period Pain Is More Than Normal: Ugandan Women Battle Endometriosis and Infertility Nilepost News
Published: July 2, 2025, 2:27 p.m.
When Period Pain Is More Than Normal: Ugandan Women Battle Endometriosis and Infertility - nilepost.co.ug
When Period Pain Is More Than Normal: Ugandan Women Battle Endometriosis and Infertility nilepost.co.ug
Published: July 2, 2025, 2:27 p.m.
Organon’s Endometriosis Drug Discontinued After Failing To Improve Pain - BioSpace
Organon’s Endometriosis Drug Discontinued After Failing To Improve Pain BioSpace
Published: July 2, 2025, 2:08 p.m.
Women with endometriosis-associated infertility are more likely to become pregnant, study reveals - News-Medical
Women with endometriosis-associated infertility are more likely to become pregnant, study reveals News-Medical
Published: July 2, 2025, 1:30 p.m.
Endometriosis Therapeutics: A Market in Need, but Can Organon Still Lead? - AInvest
Endometriosis Therapeutics: A Market in Need, but Can Organon Still Lead? AInvest
Published: July 2, 2025, 1:04 p.m.
Organon halts development of endometriosis pain drug after trial failure By Investing.com - Investing.com Nigeria
Organon halts development of endometriosis pain drug after trial failure By Investing.com Investing.com Nigeria
Published: July 2, 2025, 12:52 p.m.
Organon Provides Update on Phase 2 ELENA Proof-Of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain - MarketScreener
Organon Provides Update on Phase 2 ELENA Proof-Of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain MarketScreener
Published: July 2, 2025, 12:51 p.m.
Organon Ends Development of OG-6219 After Endometriosis Trial Fails to Meet Primary Endpoint - MarketScreener
Organon Ends Development of OG-6219 After Endometriosis Trial Fails to Meet Primary Endpoint MarketScreener
Published: July 2, 2025, 12:10 p.m.
Link copied to clipboard!